Transarterial chemoembolization combined with lenvatinib vs transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: A systematic review and meta-analysis

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 6

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

HTML

111

Figures (1-2)

Tables (1-4)

Sum=199

Publishing Process of This Article

Item

Count

Browse

Download

Sum=31

Jun 15, 2025 (publication date) through Jun 16, 2025

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Meta-Analysis

World J Gastrointest Oncol. Jun 15, 2025; 17(6): 105887
Published online Jun 15, 2025. doi: 10.4251/wjgo.v17.i6.105887

Full Size Figure Download Figure

Figure 1 PRISMA flow diagram. TACE: Transarterial chemoembolization.

Citation: Zhang W, Fu H, Liu ZR, Xu L, Che X, Ning YT, Zhan ZY, Zhou GC. Transarterial chemoembolization combined with lenvatinib vs transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: A systematic review and meta-analysis. World J Gastrointest Oncol 2025; 17(6): 105887
URL: https://www.wjgnet.com/1948-5204/full/v17/i6/105887.htm
DOI: https://dx.doi.org/10.4251/wjgo.v17.i6.105887